Introduction {#sec1-0300060517713591}
============

The risk of cardiovascular disease (CVD) is increased among patients with inflammatory arthritis (IA) (including rheumatoid arthritis \[RA\], psoriatic arthritis \[PsA\], and ankylosing spondylitis \[AS\]).^[@bibr1-0300060517713591],[@bibr2-0300060517713591]^ This increased risk is possibly related to accelerated atherosclerosis in the context of chronic inflammation.^[@bibr3-0300060517713591],[@bibr4-0300060517713591]^ Several studies have shown a 50% to 60% higher risk of death from myocardial infarction and stroke in patients with RA than in the general non-RA population,^[@bibr5-0300060517713591][@bibr6-0300060517713591]--[@bibr7-0300060517713591]^ with the standardized mortality ratio attributable to CVD ranging from 1.13 to 5.15.^[@bibr8-0300060517713591],[@bibr9-0300060517713591]^ An increased risk of CVD has also been reported in patients with PsA and AS.^[@bibr10-0300060517713591][@bibr11-0300060517713591]--[@bibr12-0300060517713591]^ Like patients with diabetes mellitus (DM), patients with RA have a two-fold higher risk of CVD compared with the general population.^[@bibr13-0300060517713591],[@bibr14-0300060517713591]^ Evidence-based guidelines have been promoted to optimize the CVD risk in high-risk populations such as those with DM, resulting in higher awareness of the CVD risk in patients with DM among primary care physicians. However, these guidelines do not currently mention IA as a risk factor for CVD. Thus, CVD risk reduction in this high-risk population may not be strongly emphasized by these doctors.^[@bibr15-0300060517713591]^

Management of the risk factors for CVD, such as high cholesterol levels, can reduce the risk of CVD; however, such management may be suboptimal in patients with IA.^[@bibr16-0300060517713591]^ For example, a recent study reported that about 40% of patients with RA who had CVD risk factors were not screened for hyperlipidemia even after having experienced a CVD event.^[@bibr17-0300060517713591]^ However, few studies have examined hyperlipidemia treatment patterns in patients with IA among those with an elevated CVD risk. We used data from the national REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort to compare hyperlipidemia treatment of participants with and without IA, controlling for individual-level factors that influence utilization of health services as conceptualized by Aday and Andersen.^[@bibr18-0300060517713591]^

Methods {#sec2-0300060517713591}
=======

Participants {#sec3-0300060517713591}
------------

The REGARDS cohort includes 30,239 community-dwelling black and white adults from the 48 contiguous United States recruited from 2003 to 2007. All were assessed with a telephone survey and in-home visit that included a blood draw and pill bottle review.^[@bibr19-0300060517713591]^ IA was identified through medications specific to autoimmune disease ([Table 1](#table1-0300060517713591){ref-type="table"}). Individuals with IA (without DM or hypertension) were compared with individuals with DM (with or without hypertension but no IA); those with hypertension (but no diabetes or IA); and those without IA, DM, or hypertension. The risk of CVD was assessed at the time of the REGARDS baseline following Adult Treatment Panel III recommendations, which were in force at the time of the study.^[@bibr20-0300060517713591]^ The study sample included only participants with indications for lipid treatment according to these guidelines (See Appendix for definition of hyperlipidemia). This study was approved by the Institutional Review Board at the University of Alabama at Birmingham. Table 1.List of medications for autoimmune disease used to identify participants with inflammatory arthritis within the REGARDS cohort.MethotrexateLeflunomideAdalimumabEtanerceptCertolizumabGolimumabHydroxychloroquineAbataceptRituximabTocilizumabGoldTofacinitib

Variables {#sec4-0300060517713591}
---------

The Aday and Andersen framework accounts for individual influences on access to healthcare including predisposing, enabling, and need factors. REGARDS collected detailed information regarding many variables within each construct of this framework.^[@bibr18-0300060517713591]^ These variables were collected at the time of the REGARDS baseline through telephone interviews, self-administered questionnaires, and in-home examinations. Information included the participants' age, race, sex, region of residence, education, household income, cigarette smoking status, alcohol consumption, marital status, cognitive function, symptoms of depression, current antihypertensive medication use, use of pills or insulin for treatment of DM, and self-reports of a previous diagnosis of myocardial infarction, coronary revascularization, stroke, abdominal aortic aneurysm, or DM. During the in-home study visits, prescription and over-the-counter medications were documented through a pill bottle review. Participants underwent a physical examination including measurement of systolic blood pressure, which was estimated based on the average of two measurements after a seated 5-minute rest with both feet on the floor. Height and weight were also measured during this examination. Blood samples were collected, and cholesterol levels were assessed in a central laboratory at the University of Vermont.

Statistical analysis {#sec5-0300060517713591}
--------------------

We used descriptive statistics to characterize the cohort according to the four groups of interest: participants with IA only, without DM or hypertension; participants with DM with or without hypertension but no IA; participants with hypertension without IA or DM; and participants without IA, hypertension, or DM. Logistic regression models were used to examine the odds of treatment among the four groups of interest (comparing the first three groups to participants without IA, DM, or hypertension) after accounting for predisposing, enabling, and need factors guided by Aday and Andersen's model of health services utilization.^[@bibr18-0300060517713591]^ Missing information was imputed by chained equations with m = 20 imputations and 10 iterations.^[@bibr21-0300060517713591]^ The analysis was conducted using SAS software (SAS Institute Inc., Cary, NC, USA).

Results {#sec6-0300060517713591}
=======

In total, 39 participants had only IA, 5423 had DM with or without hypertension but no IA, 7534 had hypertension but no IA or DM, and 5288 had no DM, hypertension, or IA. Proportionately fewer patients with than without IA were treated with lipid medications ([Figure 1](#fig1-0300060517713591){ref-type="fig"}). Hyperlipidemic participants with IA were younger and predominately women, with lower Framingham risk scores and lower functional status ([Table 2](#table2-0300060517713591){ref-type="table"}). The unadjusted model revealed that the likelihood of treatment with lipid medications was similar between individuals with IA and individuals without IA, DM, or hypertension. The fully adjusted odds of treatment for participants with IA were 27% lower than the odds for participants without IA, DM, or hypertension, or IA, although the difference was not statistically significant ([Table 3](#table3-0300060517713591){ref-type="table"}). Participants with DM with or without hypertension but no IA and participants with hypertension and no IA or DM were twice as likely to be treated for hyperlipidemia than those without IA, DM, or hypertension. Figure 1.Hyperlipidemia treatment among different populations. Table 2.Characteristics of REGARDS participants with hyperlipidemia^[\#](#table-fn7-0300060517713591){ref-type="table-fn"}^ at the time of enrollment.Andersen model domain/VariableParticipants with IA only (no DM or HTN)Participants with DM with or without hypertension (no IA)Participants with HTN (no IA or DM)Participants with no IA, DM, or HTNn = 39n = 5423n = 7534n = 5288Predisposing factors Blacks, n (%)10 (25.6)2967 (54.7)3137 (41.6)1363 (25.8) Female, n (%)23 (59.0)2896 (53.4)4063 (53.9)2312 (43.7) Age (years), mean ± standard  deviation63.3 ± 9.465.7 ± 8.766.7 ± 9.164.3 ± 9.2 Less than high school  education, n (%)0 (0.0)1000 (18.5)991 (13.2)479 (9.1)Enabling factors No health insurance, n (%)2 (5.1)373 (6.9)417 (5.5)326 (6.2) Residing in a community  with \>25%  living below the  poverty line\*, n (%)5 (13.5)1556 (31.7)1655 (24.3)893 (18.7) Annual household income of  \< \$20,000, n (%)5 (12.8)1371 (25.3)1446 (19.2)629 (11.9) Rural residence\*, n (%)5 (12.8)506 (9.3)696 (9.2)611 (11.6)Perceived need factors Aware of high cholesterol, n (%)23 (59.0)3829 (71.1)5355 (71.6)3235 (61.9) Perfect medication  adherence, n (%)28 (71.8)3539 (67.9)5009 (69.3)3175 (70.6) Current smoking, n (%)10 (25.6)736 (13.6)1083 (14.4)900 (17.0)Evaluated need factors BMI \>30 kg/m^2^, n (%)11 (28.2)3053 (56.9)2987 (39.8)1367 (25.9) Low HDL-C^[†](#table-fn7-0300060517713591){ref-type="table-fn"}^, n (%)11 (28.2)2662 (49.1)2879 (38.2)1837 (34.7) LDL-C, mg/dL,  mean ± standard  deviation122.6 ± 35.2108.4 ± 35.9120.9 ± 36.9132.7 ± 37.7 SBP, mmHg,  mean ± standard deviation125.0 ± 16.0131.1 ± 17.0131.2 ± 16.9123.3 ± 14.9 PCS, median \[25th,  75th percentile\]42.3 \[33.2, 52.1\]44.3 \[33.2, 52.0\]48.8 \[39.2, 53.8\]52.6 \[46.2, 55.7\] History of CHD, n (%)11 (28.2)1523 (28.1)1970 (26.1)907 (17.2) AHT medication use, n (%)0 (0.0)3981 (75.8)6686 (94.4)0 (0.0) Framingham Risk Score, median  \[25th, 75th percentile\]5.0 \[2.0, 12.0\]10.0 \[4.0, 16.0\]11.0 \[5.0, 17.0\]8.0 \[3.0, 12.0\][^1][^2][^3][^4] Table 3.Results of multivariable adjusted analysis for odds of treatment for high cholesterol.Participants with IA only (no DM or HTN)Participants with DM with or without hypertension (no IA)Participants with HTN (no IA or DM)Participants with no IA, DM, or HTNn = 39n = 5423n = 7534n = 5288Unadjusted model[\*\*](#table-fn11-0300060517713591){ref-type="table-fn"}0.82 (0.43, 1.59)2.23 (2.07, 2.41)1.74 (1.63, 1.88)1 (ref)Fully adjusted model‡0.73 (0.34, 1.55)2.72 (2.46, 3.00)1.97 (1.81, 2.15)1 (ref)[^5][^6][^7]

Discussion {#sec7-0300060517713591}
==========

In this study, hyperlipidemic participants with IA were less likely to be treated for hyperlipidemia than were participants with DM or hypertension, diseases well known to increase the risk of CVD, even after accounting for the CVD risk level. In fact, those with IA may have had lower odds of treatment than others with a similar CVD risk but without IA, DM, or hypertension, although the small number of participants with IA limited the power of this study. If confirmed in larger samples, these results reflect a potential gap in the management of hyperlipidemia for patients with IA. Because the multivariable models accounted for individual-level factors that influence the utilization of health services, other influences may be at play, such as suboptimal prescribing practices by physicians.

Our results identify a gap in the management of hyperlipidemia, reflecting the need for a multidisciplinary approach that includes rheumatologists and primary care physicians.^[@bibr22-0300060517713591]^ Clearly establishing which physician is taking the lead in the screening and management of CVD risk factors among patients with inflammatory joint disease is crucial for a successful approach to this comorbidity. Indeed, CVD risk factor management is not commonly within the scope of practice of rheumatologists, who may recognize that their patients with IA are at high risk but may not feel comfortable managing hyperlipidemia. Because clinical practice guidelines for the management of hyperlipidemia do not currently include patients with IA as a high-risk group, primary care physicians may not be as aware of this higher risk in patients with IA compared with those with DM, who are specifically recognized in the guidelines.

Inflammation plays a major role in the acceleration of atherosclerosis in patients with IA. There appears to be usefulness in biomarkers that can serve as a surrogate for endothelial damage, which can lead to accelerated atherosclerosis in these patients. One study identified dimethylarginines as a possible mediator of endothelial damage as well as a biomarker of CVD in patients with RA.^[@bibr23-0300060517713591]^ More recently, recommendations from the European League Against Rheumatism highlighted the importance of tight control of RA disease activity and inflammation to prevent CVD events. These guidelines emphasize the importance of screening and management of hyperlipidemia as well as other modifiable CVD risk factors not only among patients with RA but also among those with PsA and AS.^[@bibr24-0300060517713591]^ The benefits of aggressive CVD risk optimization have resulted in decreased CVD mortality among patients with DM. A similar approach may benefit patients with IA, but our results reflect a gap in the current treatment patterns.^[@bibr25-0300060517713591]^

Our study has several strengths, including the use of data from a prospective cohort that included African-Americans and Caucasians from rural and urban areas in 48 of the 50 United States. Our study has extensive patient-level data, including medications, health behaviors, and physiologic measures, allowing for control of multiple possible cofounders not previously reported. Several limitations should also be noted. IA was defined using medications specific for IA, which could have led to misclassification of some patients, although the specificity of the medications for IA lessens this concern. The small sample of patients with IA is another potential limitation, but the concern is lessened by the very narrow confidence intervals around the point estimates, suggesting little variability in the finding.

In conclusion, the treatment of hyperlipidemia in patients with IA in this sample was suboptimal compared with other conditions known to similarly increase the risk of CVD, such as hypertension and DM. Interventions to improve the treatment of hyperlipidemia in this recently recognized high-risk group may be needed.
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Patients who met these criteria were considered to have hyperlipidemiaHistory of CHD or CHD risk equivalent[\*](#table-fn2-0300060517713591){ref-type="table-fn"}, or ATP III 10-year Framingham CHD risk score of \> 20%+ LDL-C of ≥100 mg/dL-- Risk score of 10% to 20% + LDL-C of ≥130 mg/dL-- Risk score of \<10% +\<2 risk factors[\*\*](#table-fn3-0300060517713591){ref-type="table-fn"} + LDL-C of ≥160 mg/dL-- Risk score of \<10% +≥2 risk factors[\*\*](#table-fn3-0300060517713591){ref-type="table-fn"} + LDL-C of ≥130 mg/dLTo define hyperlipidemia when LDL-C level was missing, we used the following criteria:If LDL-C level was missing, then non-HDL-C[\*\*\*](#table-fn4-0300060517713591){ref-type="table-fn"} levels were used:-- History of CHD or CHD risk equivalent[\*](#table-fn2-0300060517713591){ref-type="table-fn"}, or ATP III 10-year Framingham CHD risk score of \>20% + non-HDL-C of ≥130 mg/dL-- Risk score of 10% to 20% + non-HDL-C of ≥160 mg/dL-- Risk score of \<10% + \<2 risk factors[\*\*](#table-fn3-0300060517713591){ref-type="table-fn"} + non-HDL-C of ≥190 mg/dL-- Risk score of \<10% + ≥2 risk factors[\*\*](#table-fn3-0300060517713591){ref-type="table-fn"} + non-HDL-C of ≥160 mg/dL[^8][^9][^10][^11]

[^1]: Data are presented as n (%), mean ± standard deviation, or median \[25th, 75th percentile\].

[^2]: *Abbreviations:* AHT: antihypertensive, BMI: body mass index, CHD: coronary heart disease, DM: diabetes mellitus, HDL-C: high-density lipoprotein cholesterol, HTN: hypertension, IA: inflammatory arthritis, LDL-C: low-density lipoprotein cholesterol, PCS: physical component summary score, SBP: systolic blood pressure.

[^3]: See Supplement A for definition of hyperlipidemia.

[^4]: HDL-C: Men , \<40 mg/dL; Women, \<50 mg/dL. \*Data based on census tracts.

[^5]: *Abbreviations:* IA: inflammatory arthritis, DM: diabetes mellitus, HTN: hypertension.

[^6]: Hyperlipidemia treatment outcome included treatment with statins, fibrates, or niacin.

[^7]: Unadjusted model included only disease group. ^‡^Fully adjusted model included race, sex, education, region, health insurance status, neighborhood poverty, household income, rural residence, awareness of hyperlipidemia status, medication adherence, obesity, physical component summary score, history of coronary heart disease, and Adult Treatment Panel III Framingham Risk Score.

[^8]: *Abbreviations:* CHD: coronary heart disease, ATP III: Adult Treatment Panel, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol

[^9]: CHD= myocardial infarction, coronary artery bypass grafting, bypass, angioplasty, stenting, or electrocardiographic evidence of myocardial infarction; CHD risk equivalent = stroke, abdominal aortic aneurysm, peripheral arterial disease, or diabetes

[^10]: Risk factors= hypertension (systolic blood pressure \>140 mmHg and/or diastolic blood pressure \>90 mmHg), current smoking, male, family history of CHD, low HDL-C (\<40 mg/dL for males,\< 50 mg/dL for females)

[^11]: non-HDL-C = total cholesterol− HDL-C
